As biotechnology firms become the darlings of Hong Kong’s IPO market, their executives get outsized pay packets. Here’s why

Biotechnology firms, one of the two targets in Hong Kong’s largest listing reforms in three decades, have become the latest darlings of Asia’s second-biggest capital market, making their chief …
( read original story …)

---